论文部分内容阅读
目的探讨艾迪注射液联合顺铂同步化疗对Ⅳ期非小细胞肺癌(NSCLC)寡转移患者血清高迁移率族蛋白B1(HMGB1)水平及生存质量的影响。方法选取泰州市第二人民医院2012年1月—2016年6月收治的Ⅳ期NSCLC寡转移患者58例,采用随机数表法分为对照组与观察组,每组29例。对照组给予顺铂+多西他赛化疗,观察组在对照组基础上加用艾迪注射液治疗;共治疗3个化疗周期。比较两组患者临床疗效、治疗前后血清HMGB1水平、治疗期间毒副作用/不良反应发生情况及治疗后生存质量。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前两组患者血清HMGB1水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血清HMGB1水平低于对照组(P<0.05)。两组患者恶心/呕吐、耳鸣、骨髓抑制、心动过速、发热发生率比较,差异无统计学意义(P>0.05)。观察组患者治疗后生存质量优于对照组(P<0.05)。结论艾迪注射液联合顺铂治疗Ⅳ期NSCLC寡转移患者的临床疗效确切,可有效降低患者血清HMGB1水平,改善患者生存质量,且安全性较高。
Objective To investigate the effect of Aidi Injection combined with cisplatin on serum high mobility group box 1 (HMGB1) and quality of life in patients with stage Ⅳ non-small cell lung cancer (NSCLC) oligometacidisis. Methods Fifty-eight NSCLC patients with stage Ⅳ NSCLC admitted from No.2 People’s Hospital of Taizhou from January 2012 to June 2016 were divided into control group and observation group with 29 cases in each group. The control group was treated with cisplatin plus docetaxel. The observation group was treated with Aidi Injection on the basis of the control group. A total of 3 cycles of chemotherapy were treated. The clinical efficacy, serum HMGB1 level before and after treatment, side effects / side effects during treatment and quality of life after treatment were compared between the two groups. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). There was no significant difference in serum HMGB1 level between the two groups before treatment (P> 0.05). The serum HMGB1 level in the observation group was lower than that in the control group after treatment (P <0.05). The difference of nausea / vomiting, tinnitus, bone marrow suppression, tachycardia and fever among the two groups had no statistical significance (P> 0.05). The quality of life in the observation group was better than that in the control group (P <0.05). Conclusion Aidi injection combined with cisplatin in the treatment of patients with stage Ⅳ NSCLC oligodendrocyte metastasis has definite curative effect, which can effectively reduce the level of serum HMGB1 and improve the quality of life of patients with high safety.